

OUR TEAM ([HTTPS://SLAYBACK-PHARMA.COM/OUR-STAFF/](https://slayback-pharma.com/our-staff/) )



(<https://slayback-pharma.com/products/>)



LATEST NEWS ([HTTPS://WWW.PRNEWSWIRE.COM/NEWS/SLAYBACK-PHARMA-LLC/](https://www.prnewswire.com/news/slayback-pharma-llc/) )

pharma.com )

CAREERS ([HTTPS://SLAYBACK-PHARMA.COM/CAREERS/](https://slayback-pharma.com/careers/) )

CONTACT ([HTTPS://SLAYBACK-PHARMA.COM/CONTACT/](https://slayback-pharma.com/contact/) )

Feb 4, 2021 Slayback Pharma announces launch of Merzee (norethindrone acetate generic equivalent of Taytulla

# WELCOME TO SLAYBACK PHARMA

Slayback is a New Jersey-based company focused on complex generic and specialty pharmaceutical products with a team of 85 employees and operations in the U.S., India and Europe. Since its inception in 2011, Slayback has demonstrated a spectacular track record of numerous sole first-to-file ANDAs, 505(b)(2)s and complex generic filings, approvals and launches. In the past year, Slayback’s ANDA for Hydroxyprogesterone 5 ml vial was the first generic ANDA to be approved and launched in the U.S., and Slayback continues to hold the largest market share. Previously, Slayback has shown its excellent execution skills through the approval and launch of numerous difficult products such as Propofol Injectable Emulsion.



LATEST NEWS

(<https://slayback-pharma.com/wp-content/uploads/2021/11/MYOLDMEDS-ltr-to-return-drugs->

OUR TEAM (HTTPS://SLAYBACK-PHARMA.COM/OUR-STAFF/ )  
 LATEST NEWS (HTTPS://WWW.PRNEWswire.COM/NEWS/SLAYBACK-PHARMA-LLC/ )  
 CAREERS (HTTPS://SLAYBACK-PHARMA.COM/CAREERS/ )



CONTACT (HTTPS://SLAYBACK-PHARMA.COM/CONTACT/ )  
 (https://www.prnewswire.com/news-releases  
 /slayback-appoints-paul-campanelli-to-board-of-  
 directors-301236356.html)

“ SLAYBACK APPOINTS PAUL CAMPANELLI TO BOARD OF DIRECTORS ”

VIEW DETAIL (HTTPS://WWW.PRNEWswire.COM/NEWS-RELEASES /SLAYBACK-APPOINTS-PAUL-CAMPANELLI-TO-BOARD-OF-DIRECTORS-

(https://www.prnewswire.com/news-releases  
 /slayback-pharma-appoints-dr-sumitra-pillai-as-  
 head-of-rd-301187282.html)

“ SLAYBACK PHARMA APPOINTS DR SUMITRA PILLAI AS HEAD OF RESEARCH AND DEVELOPMENT ”

VIEW DETAIL (HTTPS://WWW.PRNEWswire.COM/NEWS-RELEASES /SLAYBACK-PHARMA-APPOINTS-DR-SUMITRA-PILLAI-AS-HEAD-OF-

(https://www.prnewswire.com/news-releases  
 /slayback-appoints-dave-picard-as-chief-  
 commercial-officer-301228712.html)

“ SLAYBACK APPOINTS DAVE PICARD AS CHIEF COMMERCIAL OFFICER ”

VIEW DETAIL (HTTPS://WWW.PRNEWswire.COM/NEWS-RELEASES /SLAYBACK-APPOINTS-DAVE-PICARD-AS-CHIEF-COMMERCIAL-OFFICER-

(https://www.prnewswire.com/news-releases  
 /slayback-pharma-announces-fda-approval-of-  
 merzee-generic-equivalent-of-taytulla-with-  
 a-competitive-generic-therapy-cgt-designation-  
 301196210.html)

“ SLAYBACK PHARMA ANNOUNCES FDA APPROVAL OF MERZEE, GENERIC EQUIVALENT OF TAYTULLA WITH A COMPETITIVE GENERIC

VIEW DETAILS (HTTPS://WWW.PRNEWswire.COM/NEWS-RELEASES /SLAYBACK-PHARMA-ANNOUNCES-FDA-APPROVAL-OF-MERZEE-GENERIC-EQUIVALENT-OF-TAYTULLA-WITH-A-COMPETITIVE-GENERIC-



Slayback Pharma LLC

☎ (tel:(+1) 609 945 3443) (+1) 609 945 3443 (tel:(+1) 609 945 3443)

✉ (mailto:contact@slayback-pharma.com) contact@slayback-pharma.com (mailto:contact@slayback-pharma.com)

301 Carnegie Center, Suite 303, Princeton, NJ 08540 (<https://www.google.com/maps/place/>)



LATEST NEWS ([HTTPS://WWW.PRNEWSWIRE.COM/NEWS/SLAYBACK-PHARMA-LLC/](https://www.prnewswire.com/news/slayback-pharma-llc/) )

CAREERS ([HTTPS://SLAYBACK-PHARMA.COM/CAREERS/](https://slayback-pharma.com/careers/) )

CONTACT ([HTTPS://SLAYBACK-PHARMA.COM/CONTACT/](https://slayback-pharma.com/contact/) )

Copyright ©2021 all rights reserved